Literature DB >> 28993906

Antiangiogenesis and medical therapy failure in intracranial atherosclerosis.

Nestor R Gonzalez1, Raymond Liou2, Florian Kurth3, Hao Jiang4, Jeffrey Saver5.   

Abstract

Intracranial atherosclerotic disease (ICAD) is one of the most common causes of stroke worldwide and the one with the worst prognosis. In this study, we assessed the hypothesis that the balance of circulating pro- and antiangiogenic factors plays a role in the evolution of the disease and can be used as a potential marker for the disease course and a target for treatment. Seventy-four patients with severe ICAD were enrolled in this prospective observational study, medically optimized, and followed for 6 months. Thirteen pro- and eight antiangiogenic factors were measured in the participants' serum using a sandwich multiplex ELISA. Angiogenic profiles were calculated using principal component analysis. We tested the association between angiogenic profiles and recurring cerebrovascular events despite intensive medical therapy, disability at 6 months after enrollment, and angiographic neovascularization in patients who failed medical treatment and underwent indirect revascularization surgery. There is a strong association between a functionally antiangiogenic profile and recurrent stroke or TIA in patients with ICAD (OR = 7.2, CI 2.4-34.4). Multivariable regression analysis showed that this antiangiogenic profile was also associated with poor functional status after 6 months (p = 0.002), independent from other clinical features such as history of previous stroke, diabetes, and age. In patients who failed medical management and underwent indirect revascularization surgery, high endostatin and angiostatin levels were also associated with low angiographic neovascularization (p = 0.02). The results of this study point to the striking importance of antiangiogenesis as a determinant of ICAD patient prognosis and suggest a possible new target for therapy.

Entities:  

Keywords:  Angiogenesis; Angiostatin; Endostatin; Intracranial atherosclerosis; Stroke; TIA

Mesh:

Substances:

Year:  2017        PMID: 28993906      PMCID: PMC5831393          DOI: 10.1007/s10456-017-9578-1

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  25 in total

Review 1.  Therapeutic angiogenesis: review of current concepts and future directions.

Authors:  Wael Abo-Auda; Raymond L Benza
Journal:  J Heart Lung Transplant       Date:  2003-04       Impact factor: 10.247

2.  South Asian patients with ischemic stroke: intracranial large arteries are the predominant site of disease.

Authors:  Deidre A De Silva; Fung-Peng Woon; Moi-Pin Lee; Christopher P L H Chen; Hui-Meng Chang; Meng-Cheong Wong
Journal:  Stroke       Date:  2007-07-26       Impact factor: 7.914

3.  Power Doppler imaging in detection of surgically induced indirect neoangiogenesis in adult moyamoya disease.

Authors:  Fabienne Perren; Peter Horn; Peter Vajkoczy; Peter Schmiedek; Stephen Meairs
Journal:  J Neurosurg       Date:  2005-11       Impact factor: 5.115

Review 4.  Introduction to principal components analysis.

Authors:  Kristin L Sainani
Journal:  PM R       Date:  2014-02-22       Impact factor: 2.298

5.  Indirect revascularization for nonmoyamoya intracranial arterial stenoses: clinical and angiographic outcomes.

Authors:  Joshua R Dusick; David S Liebeskind; Jeffrey L Saver; Neil A Martin; Nestor R Gonzalez
Journal:  J Neurosurg       Date:  2012-05-04       Impact factor: 5.115

6.  Decreased levels of angiogenic growth factors in intracranial atherosclerotic disease despite severity-related increase in endothelial progenitor cell counts.

Authors:  A Massot; M Navarro-Sobrino; A Penalba; J F Arenillas; D Giralt; M Ribó; C A Molina; J Alvarez-Sabín; J Montaner; A Rosell
Journal:  Cerebrovasc Dis       Date:  2013-02-14       Impact factor: 2.762

7.  Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.

Authors:  Sanjay Rajagopalan; Emile R Mohler; Robert J Lederman; Farrell O Mendelsohn; Jorge F Saucedo; Corey K Goldman; John Blebea; Jennifer Macko; Paul D Kessler; Henrik S Rasmussen; Brian H Annex
Journal:  Circulation       Date:  2003-09-22       Impact factor: 29.690

Review 8.  Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier.

Authors:  Philip B Gorelick; Ka Sing Wong; Hee-Joon Bae; Dilip K Pandey
Journal:  Stroke       Date:  2008-06-05       Impact factor: 7.914

9.  Middle cerebral artery atherosclerosis: histological comparison between plaques associated with and not associated with infarct in a postmortem study.

Authors:  Xiang Yan Chen; Ka Sing Wong; Wynnie Wai Man Lam; Hai-Lu Zhao; Ho Keung Ng
Journal:  Cerebrovasc Dis       Date:  2007-11-22       Impact factor: 2.762

10.  Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study.

Authors:  R L Sacco; D E Kargman; Q Gu; M C Zamanillo
Journal:  Stroke       Date:  1995-01       Impact factor: 7.914

View more
  12 in total

1.  Differential Expression of Vascular Endothelial Growth Factor-A165 Isoforms Between Intracranial Atherosclerosis and Moyamoya Disease.

Authors:  Hao Jiang; Juan F Toscano; Michael Schiraldi; Shlee S Song; Konrad H Schlick; Oana M Dumitrascu; Raymond Liou; Patrick D Lyden; Jianwei Pan; Renya Zhan; Jeffrey L Saver; Nestor R Gonzalez
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-11-02       Impact factor: 2.136

2.  Mitofusin-2 regulates inflammation-mediated mouse neuroblastoma N2a cells dysfunction and endoplasmic reticulum stress via the Yap-Hippo pathway.

Authors:  Shu Hou; Lili Wang; Guoping Zhang
Journal:  J Physiol Sci       Date:  2019-05-27       Impact factor: 2.781

3.  Melatonin ameliorates endoplasmic reticulum stress in N2a neuroblastoma cell hypoxia-reoxygenation injury by activating the AMPK-Pak2 pathway.

Authors:  Jin Xing; Hao Xu; Chaobo Liu; Zilong Wei; Zhihan Wang; Liang Zhao; Li Ren
Journal:  Cell Stress Chaperones       Date:  2019-04-12       Impact factor: 3.667

4.  Hippo/Mst1 overexpression induces mitochondrial death in head and neck squamous cell carcinoma via activating β-catenin/Drp1 pathway.

Authors:  Chao Ma; Longkun Fan; Jingxian Wang; Lixia Hao; Jinqiu He
Journal:  Cell Stress Chaperones       Date:  2019-05-24       Impact factor: 3.667

5.  Sirtuin 3 inhibition induces mitochondrial stress in tongue cancer by targeting mitochondrial fission and the JNK-Fis1 biological axis.

Authors:  Jichi Zhou; Menghan Shi; Man Li; Long Cheng; Jinsuo Yang; Xin Huang
Journal:  Cell Stress Chaperones       Date:  2019-01-17       Impact factor: 3.667

6.  Irisin ameliorates septic cardiomyopathy via inhibiting DRP1-related mitochondrial fission and normalizing the JNK-LATS2 signaling pathway.

Authors:  Ying Tan; Haichun Ouyang; Xiaochan Xiao; Jiankai Zhong; Maolong Dong
Journal:  Cell Stress Chaperones       Date:  2019-04-16       Impact factor: 3.667

7.  Genetic ablation of TAZ induces HepG2 liver cancer cell apoptosis through activating the CaMKII/MIEF1 signaling pathway.

Authors:  Yi Hou; Chunna Lan; Ying Kong; Chunjiao Zhu; Wenna Peng; Zhichao Huang; Changjie Zhang
Journal:  Onco Targets Ther       Date:  2019-03-01       Impact factor: 4.147

8.  Mst1 overexpression combined with Yap knockdown augments thyroid carcinoma apoptosis via promoting MIEF1-related mitochondrial fission and activating the JNK pathway.

Authors:  Xiaoli Zhang; Fei Li; Yeqing Cui; Shuang Liu; Haichen Sun
Journal:  Cancer Cell Int       Date:  2019-05-22       Impact factor: 5.722

9.  Large tumor suppressor kinase 2 overexpression attenuates 5-FU-resistance in colorectal cancer via activating the JNK-MIEF1-mitochondrial division pathway.

Authors:  Weilong Yao; Shengtao Zhu; Peng Li; Shutian Zhang
Journal:  Cancer Cell Int       Date:  2019-04-11       Impact factor: 5.722

10.  FOXG1 improves mitochondrial function and promotes the progression of nasopharyngeal carcinoma.

Authors:  Huajun Xi; Zhengxiang He; Cao Lv
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.